Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T6KV
|
|||
| Former ID |
DNCL001961
|
|||
| Drug Name |
GSK933776A
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Macular degeneration [ICD-11: 9B78.3; ICD-10: H35; ICD-9: 362.5] | Phase 2 | [2] | ||
| Company |
GlaxoSmithKline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027328) | |||
| REF 2 | ClinicalTrials.gov (NCT01342926) Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration. U.S. National Institutes of Health. | |||
| REF 3 | Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.